114 results
Page 2 of 6
8-K
EX-99.1
2ag4ykyou 02asigfri
10 May 22
Athenex Provides First Quarter 2022 Financial Results and Business Update
7:06am
PRE 14A
mnvx2op7389pu7rlhi
18 Apr 22
Preliminary proxy
4:15pm
POS AM
isyb5urpbmg z9uhvoz3
22 Mar 22
Prospectus update (post-effective amendment)
4:30pm
POSASR
04nbol
16 Mar 22
Automatic shelf registration (post-effective amendment)
5:21pm
8-K
EX-99.1
hffddnv 10z
16 Mar 22
Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
5:18pm
8-K
EX-99.2
xe65t
16 Mar 22
Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
5:18pm
8-K
EX-99.1
xrg0d7asncax3kx
22 Feb 22
Athenex Announces Appointment of Chief Financial Officer
4:16pm
8-K
EX-99.1
37qnwrenijk v3e
15 Feb 22
Athenex Announces Completion of Sale of Dunkirk Manufacturing Facility
9:00am
8-K
7jbkrz
21 Jan 22
Entry into a Material Definitive Agreement
4:16pm
8-K
EX-10.1
wohnu
12 Jan 22
Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility
8:36am
8-K
p6toh 42v77d50m6cy
12 Jan 22
Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility
8:36am
8-K
EX-99.1
p2o n609iz
12 Jan 22
Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility
8:36am
8-K
EX-99.1
rv9yyg
4 Nov 21
Athenex Provides Third Quarter 2021 Corporate and Financial Update
7:05am
8-K
EX-99.1
m635gj
12 Oct 21
Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar in Metastatic Breast Cancer
6:31am